Syndax Secures a Sweet $26.6M Series B
By Marie Powers
Tuesday, August 27, 2013
Syndax Pharmaceuticals Inc. moved closer to a new drug application (NDA)-enabling Phase III trial of lead candidate entinostat in metastatic breast cancer with a $26.6 million Series B financing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.